BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 16935784)

  • 21. Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment.
    Viale G
    Breast; 2009 Oct; 18 Suppl 3():S32-6. PubMed ID: 19914539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer.
    Nacht M; Ferguson AT; Zhang W; Petroziello JM; Cook BP; Gao YH; Maguire S; Riley D; Coppola G; Landes GM; Madden SL; Sukumar S
    Cancer Res; 1999 Nov; 59(21):5464-70. PubMed ID: 10554019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using specific cytotoxics with a targeted mind.
    Di Leo A; Claudino WM; Pestrin M; Licitra S; Biganzoli L
    Breast; 2007 Dec; 16 Suppl 2():S120-6. PubMed ID: 17720501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical validation of a customized multiple signature microarray for breast cancer.
    Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
    Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
    Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
    J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
    Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic analysis: toward a new approach in breast cancer management.
    Cavallaro S; Paratore S; de Snoo F; Salomone E; Villari L; Buscarino C; Ferraù F; Banna G; Furci M; Strazzanti A; Cunsolo R; Pezzino S; Gangi S; Basile F
    Crit Rev Oncol Hematol; 2012 Mar; 81(3):207-23. PubMed ID: 21511492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer.
    Tordai A; Liedtke C; Pusztai L
    Clin Exp Metastasis; 2009; 26(7):625-32. PubMed ID: 19381845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis.
    Driouch K; Landemaine T; Sin S; Wang S; Lidereau R
    Clin Exp Metastasis; 2007; 24(8):575-85. PubMed ID: 17973194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the Human Genome Project on the clinical management of sporadic cancers.
    Fey MF
    Lancet Oncol; 2002 Jun; 3(6):349-56. PubMed ID: 12107022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Towards an individualization of systemic treatment of breast tumors].
    Bernard-Marty C; Cardoso F; Sotiriou C; Piccart MJ
    Bull Cancer; 2006 Aug; 93(8):791-7. PubMed ID: 16935784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population-based molecular prognosis of breast cancer by transcriptional profiling.
    Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
    Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
    Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
    Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
    Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
    Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic applications of gene expression signatures in breast cancer.
    Normanno N; De Luca A; Carotenuto P; Lamura L; Oliva I; D'Alessio A
    Oncology; 2009; 77 Suppl 1():2-8. PubMed ID: 20130425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.